Physician profile
Cathy Benavides
NPI 1821173832
$1,680.86
in general payments reported to CMS, 2019-2025
13 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.29 · 2023: $590 · 2024: $346 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $768.42 | 2023-2025 | |
| Novo Nordisk INC | $310.69 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $138.14 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Organon LLC | $111.14 | 2023 | Nexplanon |
| Pfizer INC. | $60.37 | 2024-2025 | |
| Exact Sciences Corporation | $56.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $55.95 | 2022-2025 | Mounjaro, Zepbound |
| Spr Therapeutics, INC | $50.04 | 2025 | Sprint Pns System |
| Medtronic, INC. | $40.67 | 2023 | Vanta Adaptivestim |
| Glaxosmithkline, LLC. | $35.27 | 2023-2024 | Shingrix, Arexvy |
| Amgen INC. | $19.84 | 2025 | Repatha |
| Astellas Pharma US INC | $18.95 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $15.23 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Benavides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.